Integra LifeSciences (NASDAQ:IART) Price Target Cut to $25.00

Integra LifeSciences (NASDAQ:IART) had its price objective cut by investment analysts at Truist Financial from $37.00 to $25.00 in a research report issued on Tuesday, Benzinga reports. The brokerage presently has a “hold” rating on the life sciences company’s stock. Truist Financial’s target price indicates a potential upside of 0.36% from the stock’s previous close.

Several other research firms have also commented on IART. JMP Securities lowered their price target on shares of Integra LifeSciences from $55.00 to $49.00 and set a “market outperform” rating on the stock in a report on Thursday, February 29th. Wells Fargo & Company cut Integra LifeSciences from an “overweight” rating to an “equal weight” rating and reduced their price target for the company from $45.00 to $25.00 in a research report on Tuesday. Oppenheimer lowered Integra LifeSciences from an “outperform” rating to a “market perform” rating in a research report on Tuesday. Citigroup upgraded shares of Integra LifeSciences from a “sell” rating to a “neutral” rating and set a $38.00 target price for the company in a research note on Wednesday, April 3rd. Finally, StockNews.com cut shares of Integra LifeSciences from a “buy” rating to a “hold” rating in a report on Tuesday, April 30th. Three research analysts have rated the stock with a sell rating, six have assigned a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $36.80.

Integra LifeSciences Price Performance

Shares of IART opened at $24.91 on Tuesday. The firm has a market capitalization of $1.96 billion, a PE ratio of 30.01, a price-to-earnings-growth ratio of 0.87 and a beta of 1.17. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.45 and a quick ratio of 2.18. The company’s fifty day moving average price is $32.67 and its 200-day moving average price is $38.15. Integra LifeSciences has a 1-year low of $22.36 and a 1-year high of $50.78.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings data on Monday, May 6th. The life sciences company reported $0.55 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.55. Integra LifeSciences had a return on equity of 15.19% and a net margin of 4.39%. The business had revenue of $368.90 million for the quarter, compared to analyst estimates of $361.96 million. During the same period in the prior year, the company earned $0.74 earnings per share. The company’s revenue was down 3.2% on a year-over-year basis. On average, equities research analysts predict that Integra LifeSciences will post 3.19 EPS for the current year.

Institutional Investors Weigh In On Integra LifeSciences

Large investors have recently bought and sold shares of the company. Raymond James & Associates raised its stake in Integra LifeSciences by 28.7% in the 3rd quarter. Raymond James & Associates now owns 204,325 shares of the life sciences company’s stock valued at $7,803,000 after purchasing an additional 45,554 shares during the last quarter. Strs Ohio raised its position in shares of Integra LifeSciences by 6.9% in the third quarter. Strs Ohio now owns 41,730 shares of the life sciences company’s stock valued at $1,593,000 after buying an additional 2,679 shares during the last quarter. Advisor Partners II LLC acquired a new position in Integra LifeSciences during the third quarter worth about $241,000. Inspire Investing LLC grew its stake in Integra LifeSciences by 5.1% during the 3rd quarter. Inspire Investing LLC now owns 8,004 shares of the life sciences company’s stock valued at $306,000 after acquiring an additional 392 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its stake in Integra LifeSciences by 451.9% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 70,827 shares of the life sciences company’s stock worth $2,705,000 after purchasing an additional 57,993 shares in the last quarter. 84.78% of the stock is currently owned by hedge funds and other institutional investors.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.